Association of preoperative and postoperative serum carcinoembryonic antigen and

1. Center for Cancer Control and Information Services. National Cancer Center. Japan: Incidence of stomach cancer (National Estimates). //gdb.ganjoho.jp/graph_db/.

2. Katai H, Ishikawa T, Akazawa K, Isobe Y, Miyashiro I, Oda I, Tsujitani S, Ono H, Tanabe S, Fukagawa T, Nunobe S, Kakeji Y, Nashimoto A, Registration Committee of the Japanese Gastric Cancer Association. Five-year survival analysis of surgically resected gastric cancer cases in Japan: a retrospective analysis of more than 100,000 patients from the nationwide registry of the Japanese Gastric Cancer Association (2001–2007). Gastric Cancer. 2018;21:144–54.

   Article  Google Scholar 

3. Yu J, Huang C, Sun Y, Su X, Cao H, Hu J, Wang K, Suo J, Tao K, He X, Wei H, Ying M, Hu W, Du X, Hu M, Liu H, Zheng C, Li P, Xie J, Liu F, Li Z, Zhao G, Yang K, Liu C, Li H, Chen P, Ji J, Li G, for the Chinese Laparoscopic Gastrointestinal Surgery Study (CLASS) Group. Effect of laparoscopic vs open distal gastrectomy on 3-year disease-free survival in patients with locally advanced gastric cancer: The CLASS-01 randomized clinical trial. JAMA. 2019;321:1983–92.

   Article  Google Scholar 

4. Fujiya K, Tokunaga M, Makuuchi R, Nishiwaki N, Omori H, Takagi W, Hirata F, Hikage M, Tanizawa Y, Bando E, Kawamura T, Terashima M. Early detection of nonperitoneal recurrence may contribute to survival benefit after curative gastrectomy for gastric cancer. Gastric Cancer. 2017;20:141–9.

   Article  Google Scholar 

5. Park JS, Choe EA, Park S, Nam CM, Hyung WJ, Noh SH, Lee S, Kim HS, Jung M, Chung HC, Rha SY. Detection of asymptomatic recurrence improves survival of gastric cancer patients. Cancer Med. 2021;10:3249–60.

   Article  Google Scholar 

6. Shimada H, Noie T, Ohashi M, Oba K, Takahashi Y. Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association. Gastric Cancer. 2014;17:26–33.

   CAS  Article  Google Scholar 

7. Jing R, Cui M, Ju S, Pan S. The changes and clinical significance of preoperative and postoperative serum CEA and CA19-9 in gastric cancer. Clin Lab. 2020. //doi.org/10.7754/Clin.Lab.2019.190732.

   Article  PubMed  Google Scholar 

8. Ucar E, Semerci E, Ustun H, Yetim T, Huzmeli C, Gullu M. Prognostic value of preoperative CEA, CA19-9, CA 72-4, and AFP levels in gastric cancer. Adv Ther. 2008;25:1075–84.

   Article  Google Scholar 

9. Rizeq B, Zakaria Z, Ouhtit A. Towards understanding the mechanisms of actions of carcinoembryonic antigen-related cell adhesion molecule 6 in cancer progression. Cancer Sci. 2018;109:33–42.

   CAS  Article  Google Scholar 

10. Pinkert J, Boehm HH, Trautwein M, Doecke WD, Wessel F, Ge Y, Gutierrez EM, Carretero R, Freiberg C, Gritzan U, Luetke-Eversloh M, Golfier S, Von Ahsen O, Volpin V, Sorrentino A, Rathinasamy A, Xydia M, Lohmayer R, Sax J, Nur-Menevse A, Hussein A, Stamova S, Beckmann G, Glueck JM, Schoenfeld D, Weiske J, Zopf D, Offringa R, Kreft B, Beckhove P, Willuda J. T cell-mediated elimination of cancer cells by blocking CEACAM6-CEACAM1 interaction. Oncoimmunology. 2021;11:2008110.

    Article  Google Scholar 

11. Solimando AG, Summa S, Vacca A, Ribatti D. Cancer-associated angiogenesis: the endothelial cell as a checkpoint for immunological patrolling. Cancers (Basel). 2020;12:3380.

    CAS  Article  Google Scholar 

12. Engle DD, Tiriac H, Rivera KD, Pommier A, Whalen S, Oni TE, Alagesan B, Lee EJ, Yao MA, Lucito MS, Spielman B, Da Silva B, Schoepfer C, Wright K, Creighton B, Afinowicz L, Yu KH, Grützmann R, Aust D, Gimotty PA, Pollard KS, Hruban RH, Goggins MG, Pilarsky C, Park Y, Pappin DJ, Hollingsworth MA, Tuveson DA. The glycan CA19-9 promotes pancreatitis and pancreatic cancer in mice. Science. 2019;364(6446):1156–62.

    CAS  Article  Google Scholar 

13. Kodera Y, Yamamura Y, Torii A, Uesaka K, Hirai T, Yasui K, Morimoto T, Kato T, Kito T. The prognostic value of preoperative serum levels of CEA and CA19-9 in patients with gastric cancer. Am J Gastroenterol. 1996;91:49–53.

    CAS  PubMed  Google Scholar 

14. Victorzon M, Haglund C, Lundin J, Roberts PJ. A prognostic value of CA19-9 but not of CEA in patients with gastric cancer. Eur J Surg Oncol. 1995;21:379–84.

    CAS  Article  Google Scholar 

15. Nakajima K, Ochiai T, Suzuki T, Shimada H, Hayashi H, Yasumoto A, Takeda A, Hishikawa E, Isono K. Impact of preoperative serum carcinoembryonic antigen, CA19-9 and alpha fetoprotein levels in gastric cancer patients. Tumour Biol. 1998;19:464–9.

    CAS  Article  Google Scholar 

16. Mihmanli M, Dilege E, Demir U, Coskun H, Eroglu T, Uysalol MD. The use of tumor markers as predictors of prognosis in gastric cancer. Hepatogastroenterology. 2004;51:1644–7.

    Google Scholar 

17. Tachibana M, Takemoto Y, Nakashima Y, Kinugasa S, Kotoh T, Dhar DK, Kohno H, Nagasue N. Serum carcinoembryonic antigen as a prognostic factor in resectable gastric cancer. J Am Coll Surg. 1998;187:64–8.

    CAS  Article  Google Scholar 

18. Suenaga Y, Kanda M, Ito S, Mochizuki Y, Teramoto H, Ishigure K, Murai T, Asada T, Ishiyama A, Matsushita H, Tanaka C, Kobayashi D, Fujiwara M, Murotani K, Yasuhiro KY. Prognostic significance of perioperative tumor marker levels in stage II/III gastric cancer. World J Gastrointest Oncol. 2019;11:17–27.

    Article  Google Scholar 

19. Kochi M, Fujii M, Kanamori N, Kaiga T, Kawakami T, Aizaki K, Kasahara M, Mochizuki F, Kasakura Y, Yamamoto M. Evaluation of serum CEA and CA19-9 levels as prognostic factors in patients with gastric cancer. Gastric Cancer. 2000;3:177–86.

    Article  Google Scholar 

20. Kim DY, Kim HR, Shim JH, Park CS, Kim SK, Kim YJ. Significance of serum and tissue carcinoembryonic antigen for the prognosis of gastric carcinoma patients. J Surg Oncol. 2000;74:185–92.

    CAS  Article  Google Scholar 

21. Reiter W, Stieber P, Reuter C, Nagel D, Cramer C, Pahl H, Fateh-Moghadam A. Prognostic value of preoperative serum levels of CEA, CA19-9 and CA 72–4 in gastric carcinoma. Anticancer Res. 1997;17:2903–6.

    CAS  PubMed  Google Scholar 

22. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011;14:101–12.

    Article  Google Scholar 

23. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2018 (ver. 5). Gastric Cancer. 2021;24:1–21.

    Article  Google Scholar 

24. Takahashi Y, Takeuchi T, Sakamoto J, Touge T, Mai M, Ohkura H, Kodaira S, Okajima K, Nakazato H, Tumor Marker Committee. The usefulness of CEA and/or CA19-9 in monitoring for recurrence in gastric cancer patients: a prospective clinical study. Gastric Cancer. 2003;6:142–5.

    Article  Google Scholar 

25. Duraker N, Celik AN. The prognostic significance of preoperative serum CA19-9 in patients with resectable gastric carcinoma: comparison with CEA. J Surg Oncol. 2001;76:266–71.

    CAS  Article  Google Scholar 

26. Marrelli D, Pinto E, De Stefano A, de Manzoni G, Farnetani M, Garosi L, Roviello F. Preoperative positivity of serum tumor markers is a strong predictor of hematogenous recurrence of gastric cancer. Surg Oncol. 2001;78:253–8.

    CAS  Article  Google Scholar 

27. Go VL. Carcinoembryonic antigen: clinical application. Cancer. 1976;37(1 suppl):562–6.

    CAS  Article  Google Scholar 

28. Cullen KJ, Stevens DP, Frost MA, Mackay IR. Carcinoembryonic antigen (CEA), smoking, and cancer in a longitudinal population study. Aust NZ J Med. 1976;6:279–83.

    CAS  Article  Google Scholar 

29. Tamada R, Hiramoto Y, Tsujitani S, Nozuka T, Okamura T, Masuda H, Sugimachi K, Inokuchi K. Serum CEA levels facilitate detection of recurrences of cancer in patients after gastrectomy. Jpn J Surg. 1985;15:23–9.

    CAS  Article  Google Scholar 

30. Marrelli D, Pinto E, De Stefano A, Farnetani M, Garosi L, Roviello F. Clinical utility of CEA, CA 19-9, and CA 72-4 in the follow-up of patients with resectable gastric cancer. Am J Surg. 2001;181:16–9.

    CAS  Article  Google Scholar 

31. Choi SR, Jang JS, Lee JH, Roh MH, Kim MC, Lee WS, Qureshi W. Role of serum tumor markers in monitoring for recurrence of gastric cancer following radical gastrectomy. Dig Dis Sci. 2006;51:2081–6.

    CAS  Article  Google Scholar 

32. Wang W, Chen XL, Zhao SY, Xu YH, Zhang WH, Liu K, Chen XZ, Yang K, Zhang B, Chen ZX, Chen JP, Zhou ZG, Hu JK. Prognostic significance of preoperative serum CA125, CA19-9 and CEA in gastric carcinoma. Oncotarget. 2016;7:35423–36.

    Article  Google Scholar 

33. Liu X, Qiu H, Liu J, Chen S, Xu D, Li W, Zhan Y, Li Y, Chen Y, Zhou Z, Sun X. Combined preoperative concentrations of CEA, CA19-9, and 72–4 for predicting outcomes in patients with gastric cancer after curative resection. Oncotarget. 2016;7:35446–53.

    Article  Google Scholar 

34. Nashimoto A, Yabusaki H, Nakagawa S. Proper follow-up schedule after curative gastric surgery. Jpn J Cancer Chemother. 2009;36:1402–7 (Japanese with English abstract).

    Google Scholar 

35. Noguchi Y, Imada T, Makino T, Suzuki H, Abe M, Tamura S, Yamamoto Y, Amano T, Matsumoto A. Clinical course of gastric carcinoma recurrence after surgery. J Jpn Soc Clin Surg. 1988;49:584–9 (Japanese with English abstract).

    Google Scholar 

Page 2

1. Numbers in parentheses are %
2. aClassification according to the Japanese classification of gastric carcinoma and the Gastric Cancer Treatment Guidelines in Japan